DNA methyltransferase inhibitors in hematological malignancies and solid tumors
International Journal of Cancer · 15.01.2026 · 158 (2) · 433-461
DOI: 10.1002/ijc.70197 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 07.11.2025. Verfasst von Valentin Wenger und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I (Division of Hematology, Oncology and Stem Cell Transplantation), University of Freiburg Medical Center, Faculty of Medicine…. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Enzyme Inhibitors, Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutschen Konsortium für Translationale Krebsforschung, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor suppressor genes, oncogenes, and other key regulatory genes. The first‐generation DNMTi azacitidine and decitabine have demonstrated substantial efficacy in the treatment of medically non‐fit, older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy (IC), by virtue of their favorable safety profile. Despite these clinical achievements, however, single‐agent DNMTi treatment has faced challenges such as limited, non‐durable response rates and remissions as well as the emergence of secondary resistance. These limitations have driven broad efforts to identify more effective, dual treatment combinations, such as now attained with the DNMTi‐BCL‐2 (B‐cell lymphoma 2) inhibitor combination. This review aims to provide a comprehensive overview and analysis of the pivotal role of DNMTi in both mono‐ and combination therapies for myeloid malignancies over the last 40 years, while also exploring their potential applicability in lymphoid malignancies. Additionally, this review assesses the therapeutic potential of DNMTi in the management of solid tumors. Through these discussions, we intend to enhance the understanding of the mechanistic and therapeutic implications of DNMTi across a diverse array of malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine I (Division of Hematology, Oncology and Stem Cell Transplantation), University of Freiburg Medical Center, Faculty of Medicine, Freiburg, Germany.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- German Cancer Consortium (DKTK), Partner Site Freiburg, a Partnership Between DKFZ and University of Freiburg Medical Center, Freiburg, Germany.
- Signaling Research Centres BIOSS and CIBSS - Centre for Integrative Biological Signaling Studies, University of Freiburg, Freiburg, Germany.
- German Society of Hematology and Medical Oncology (DGHO) Working Group 'Clinical and Translational Epigenetics', Germany.
ORCID-Profile: Valentin Wenger, Michael Lübbert
Förderung
- Deutschen Konsortium für Translationale Krebsforschung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Wenger, V., Garcia-Manero, G., Zeiser, R., & Lübbert, M. (2026). DNA methyltransferase inhibitors in hematological malignancies and solid tumors. International Journal of Cancer, 158(2), 433-461. https://doi.org/10.1002/ijc.70197
Vancouver
Wenger V, Garcia-Manero G, Zeiser R, Lübbert M. DNA methyltransferase inhibitors in hematological malignancies and solid tumors. International Journal of Cancer. 2026;158(2):433-461. doi:10.1002/ijc.70197
BibTeX
@article{Wenger2026,
author = {Wenger, Valentin and Garcia-Manero, Guillermo and Zeiser, Robert and Lübbert, Michael},
title = {DNA methyltransferase inhibitors in hematological malignancies and solid tumors},
journal = {International Journal of Cancer},
year = {2026},
volume = {158},
number = {2},
pages = {433--461},
doi = {10.1002/ijc.70197}
}
EUVIMED